Natco Pharma Ltd.

Natco Pharma is currently trading at Rs. 833.90, up by 9.80 points or 1.19% from its previous closing of Rs. 824.10 on the BSE.

The scrip opened at Rs. 840.00 and has touched a high and low of Rs. 850.00 and Rs. 833.00 respectively. So far 4045 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 877.00 on 06-Mar-2014 and a 52 week low of Rs. 390.00 on 16-May-2013.

Last one week high and low of the scrip stood at Rs. 863.85 and Rs. 820.00 respectively. The current market cap of the company is Rs. 2758.79 crore.

The promoters holding in the company stood at 53.70% while Institutions and Non-Institutions held 22.29% and 24.00% respectively.

Natco Pharma has received tentative approval from United States Food & Drug Administration (USFDA) for Oseltamivir Phosphate Capsules USP, 30 mg (base), 45 mg (base) and 75 mg (base). The company has partnered with Alvogen for marketing.

The company may have First-to-File approval status for the Abbreviated New Drug Application (ANDA), contingent upon successful litigation outcome of original drug patent. According to IMS Health, TAMIFLU, Roche’s trade name for Oseltamivir Phosphate had US sales of approximately $495 million for twelve months ending September 2013.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.